Mitokinin
Rishi Rakhit, PhD, serves at Mitokinin’s Director of Translational Medicine. In that capacity, Dr. Rakhit oversees the Company’s biomarker development and in vivo translational efforts.
Dr. Rakhit is the inventor of two clinical-stage antibody therapeutics and several more in pre-clinical development for neurodegenerative disease. Prior to Mitokinin, Dr. Rakhit held team and project leadership positions at Denali Therapeutics and Achaogen Inc. He has published first author papers in Nature Medicine, eLife, and others, as well as presented as an invited speaker at major international meetings.
Dr. Rakhit received his PhD in biochemistry from University of Toronto (Chakrabartty lab), and completed his post-doctoral training in protein engineering and proteomics in the lab of Tom Wandless at Stanford University.
This person is not in any teams
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.